An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension

Trial Profile

An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Mirogabalin (Primary)
  • Indications Postherpetic neuralgia
  • Focus Registrational; Therapeutic Use
  • Acronyms NEUCOURSE
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 30 Jun 2017 According to a Daiichi Sankyo media release, full results from this trial will be disclosed in upcoming scientific mediums.
    • 30 Jun 2017 Results from this trial published in a Daiichi Sankyo Media Release.
    • 30 Jun 2017 Primary endpoint (Change in the Average Daily Pain Score (ADPS))has been met, according to a Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top